- Home
- EBS vs JRI Comparison
EBS vs JRI Comparison
Compare EBS & JRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EBS
- JRI
- Stock Information
- Founded
- EBS 1998
- JRI 2012
- Country
- EBS United States
- JRI United States
- Employees
- EBS N/A
- JRI N/A
- Industry
- EBS Biotechnology: Pharmaceutical Preparations
- JRI Finance Companies
- Sector
- EBS Health Care
- JRI Finance
- Exchange
- EBS Nasdaq
- JRI Nasdaq
- Market Cap
- EBS 359.3M
- JRI 367.7M
- IPO Year
- EBS 2006
- JRI N/A
- Fundamental
- Price
- EBS $8.15
- JRI $14.23
- Analyst Decision
- EBS Strong Buy
- JRI
- Analyst Count
- EBS 3
- JRI 0
- Target Price
- EBS $14.33
- JRI N/A
- AVG Volume (30 Days)
- EBS 1.0M
- JRI 68.0K
- Earning Date
- EBS 11-05-2025
- JRI 01-01-0001
- Dividend Yield
- EBS N/A
- JRI 9.38%
- EPS Growth
- EBS N/A
- JRI N/A
- EPS
- EBS 2.53
- JRI N/A
- Revenue
- EBS $851,600,000.00
- JRI N/A
- Revenue This Year
- EBS N/A
- JRI N/A
- Revenue Next Year
- EBS $19.24
- JRI N/A
- P/E Ratio
- EBS $3.22
- JRI N/A
- Revenue Growth
- EBS N/A
- JRI N/A
- 52 Week Low
- EBS $4.02
- JRI $9.70
- 52 Week High
- EBS $12.73
- JRI $12.12
- Technical
- Relative Strength Index (RSI)
- EBS 51.40
- JRI 82.42
- Support Level
- EBS $7.45
- JRI $13.27
- Resistance Level
- EBS $8.62
- JRI $13.60
- Average True Range (ATR)
- EBS 0.40
- JRI 0.11
- MACD
- EBS -0.10
- JRI 0.07
- Stochastic Oscillator
- EBS 38.46
- JRI 99.77
About EBS Emergent Biosolutions Inc.
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.
About JRI Nuveen Real Asset Income and Growth Fund of Beneficial Interest
Nuveen Real Asset Income and Growth Fund is the United States-based closed-end fund. Its objective is to provide a high level of current income and long-term capital appreciation. The fund invests a majority of its managed assets in equity and debt securities issued by real asset related companies located anywhere in the world. Its plan involves investments in five security types, infrastructure common stock, REIT preferred stock and debt securities. Real asset-related companies include those engaged in owning, operating, or developing infrastructure projects, facilities, and services, as well as REITs.